Merck 3Q 3Q Revenues: $6.0 billion (+2%) 3Q Earnings: $3.5 billion (earnings were $1.1 billion in 3Q08) YTD Revenues: $17.3 billion (-3%) YTD Earnings: $6.5 billion (+4%) Comments: Singulair sales were $1.1 billion in the quarter (+5%). Combined global sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $1.0 billion (-7%). Global sales Cozaar and Hyzaar were $861 million in the quarter (-3%). Januvia sales were up 30% to $491 million. Gardas...